AstraZeneca reports positive results for phase 2 COAST trial of oleclumab and monalizumab
AstraZeneca has reported positive results from the COAST phase 2 trial of its oleclumab or monalizumab in combination with Imfinzi (durvalumab) in patients with non-small ... Read More
Zydus Cadila gets FDA nod for chemotherapy drug Pemetrexed generic
Cadila Healthcare (also known as Zydus Cadila) said that it has secured tentative approval from the US Food and Drug Administration (FDA) for marketing Pemetrexed ... Read More
Amgen secures breakthrough therapy designation for sotorasib in China
Amgen has achieved a major milestone in the global development of its investigational KRAS G12C inhibitor, sotorasib, with the National Medical Products Administration (NMPA) in ... Read More
AstraZeneca secures extended FDA approval for Tagrisso as adjuvant treatment in early-stage lung cancer
AstraZeneca has announced a significant breakthrough with the United States Food and Drug Administration (FDA) granting extended approval for its drug Tagrisso (osimertinib) as an ... Read More
BMS’ Opdivo plus Yervoy combo gets EC approval for metastatic NSCLC
Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of metastatic non-small ... Read More
AstraZeneca strikes $6bn worth deal for Daiichi Sankyo’s DS-1062
AstraZeneca has signed a deal potentially worth up to $6 billion with Daiichi Sankyo for the global development and commercialization for the latter's DS-1062, a ... Read More
Selpercatinib FDA approval : Lilly’s therapy approved for treatment of lung and thyroid cancers with RET alteration
Selpercatinib FDA approval : The US Food and Drug Administration (FDA) has approved Eli Lilly and Company's Retevmo (selpercatinib) capsules for the treatment of three ... Read More
Genetron Health’s semiconductor-based NGS system gets Chinese approval
Genetron Health has been granted approval by China’s National Medical Products Administration (NMPA) for GENETRON S5, its semiconductor-based next-generation sequencing system (NGS system). With the ... Read More
Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC
Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) ... Read More
Biodesix acquires Oncimmune’s laboratory and IPN malignancy test in US
Biodesix, a lung cancer diagnostic solutions company, has acquired UK-based Oncimmune’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the US, to expand its ... Read More